Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
18 Nov 2024
Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.
18 Nov 2024

Sacituzumab govitecan improves survival in advanced breast cancer
18 Nov 2024
Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.
18 Nov 2024







